Vials

AOD-9604

Name: AOD-9604
Brand: Quanta Pharmaceuticals

A modified HGH fragment (176-191) studied for fat metabolism without growth-hormone-linked anabolic activity.

AOD-9604 is a modified fragment of human growth hormone, corresponding to amino acids 176-191, engineered to retain HGH's fat-metabolising activity while eliminating its growth-promoting and blood-sugar effects. It consists of 15 amino acids. AOD-9604 has an unusually well-documented clinical history for a research peptide: in a 12-week randomised trial run by its original developer, Metabolic Pharmaceuticals, subjects receiving 1mg/day lost an average of 2.6kg versus 0.8kg on placebo. However, the follow-up Phase 2b trial — over 500 obese adults across multiple doses — failed to reach statistical significance against placebo on its primary weight-loss endpoint, and clinical development was subsequently discontinued. It remains a preclinical and in-vitro research compound rather than an approved or clinically validated fat-loss therapy. This vial is supplied at 5mg.

Verify a product

Specifications

Peptide

AOD-9604

Sequence

HGH Fragment 176-191, 15 Amino Acids

Dosage

5mg/vial

Half-Life

~2-3 hours

Administration

Subcutaneous

Form

Lyophilised

Research Benefits

Fat metabolism focus — Retains HGH's lipolytic (fat-releasing) activity without its broader growth-hormone effects.
Non-anabolic profile — Does not raise IGF-1 or affect blood glucose the way full-length HGH does.
Early clinical signal — A 12-week trial at 1mg/day reported 2.6kg lost versus 0.8kg on placebo.
Targeted fragment design — Isolates the specific region of the HGH molecule responsible for fat-oxidation signalling.

How It Works

AOD-9604 isolates the C-terminal fragment of human growth hormone (residues 176-191), the region researchers identified as responsible for HGH's effect on lipolysis — the breakdown of stored fat into usable energy — without the residues responsible for HGH's growth-promoting and insulin-desensitising effects.

Because it excludes the rest of the HGH molecule, AOD-9604 does not raise IGF-1 or affect blood glucose regulation, distinguishing its research profile from full-length growth hormone or growth hormone secretagogues. Its short 2-3 hour half-life reflects its status as a small, rapidly cleared peptide fragment. Its clinical development history is worth knowing for research context: an early-phase trial showed a modest but real weight-loss signal, while the larger pivotal trial did not confirm it against placebo, which is why it remains a research compound rather than a proven therapy.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. AOD-9604 must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.